Literature DB >> 30426231

Unraveling KDM4 histone demethylase expression and its association with adverse cytogenetic findings in chronic lymphocytic leukemia.

Luma Dayane de Carvalho Filiú-Braga1, Teresa Raquel Tavares Serejo1, Antonio Roberto Lucena-Araujo2, Francisco Assis Rocha Neves1, Juliana Lott de Carvalho3, Eduardo Magalhaes Rego4, Felipe Saldanha-Araujo5.   

Abstract

The acquisition of complex karyotypes is related to the progression of chronic lymphocytic leukemia (CLL) and patients with this condition have a poor prognosis. Despite recent advances in the classification of prognosis in CLL patients, understanding of the molecular mechanisms that lead to genomic instability and progression of this disease remains inadequate. Interestingly, dysregulated expression of KDM4 members is involved in the progression of several cancer types and plays a role in the DNA damage response; however, the gene expression profile and the importance of KDM4 members in CLL are still unknown. Here, we assessed the gene expression profile of KDM4A, KDM4B, and KDM4C in 59 CLL samples and investigated whether these histone demethylases have any influence on the prognostic markers of this leukemia. KDM4A gene expression was higher in CLL patients as compared with control samples. In contrast, CLL samples showed decreased levels of the KDM4B transcript in relation to control cases, and no difference was detected in KDM4C expression. Furthermore, patients with positive expression of ZAP-70 had lower expression of KDM4B and KDM4C as compared with ZAP-70-negative patients. More importantly, patients with low expression of these histone demethylases had higher leukemic cell numbers and displayed adverse cytogenetic findings and the acquisition of a complex karyotype. The present data clearly show that the expression of KDM4 members is dysregulated in CLL and impact the prognosis of this leukemia. These findings are useful for a better understanding of the impact of epigenetics on CLL progression.

Entities:  

Keywords:  Chronic lymphocytic leukemia; KDM4; Karyotype; Prognostic factors; ZAP-70

Mesh:

Substances:

Year:  2018        PMID: 30426231     DOI: 10.1007/s12032-018-1226-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  18 in total

Review 1.  Chronic lymphocytic leukemia: Time to go past genomics?

Authors:  Damien Roos-Weil; Florence Nguyen-Khac; Olivier A Bernard
Journal:  Am J Hematol       Date:  2016-04-04       Impact factor: 10.047

2.  Jmjd2c histone demethylase enhances the expression of Mdm2 oncogene.

Authors:  Akihiko Ishimura; Minoru Terashima; Hiroshi Kimura; Keiko Akagi; Yutaka Suzuki; Sumio Sugano; Takeshi Suzuki
Journal:  Biochem Biophys Res Commun       Date:  2009-09-02       Impact factor: 3.575

3.  Aberrant levels of SUV39H1 and SUV39H2 methyltransferase are associated with genomic instability in chronic lymphocytic leukemia.

Authors:  Juliana Carvalho Alves-Silva; Doralina do Amaral Rabello; Martha Oliveira Bravo; Antônio Lucena-Araujo; Diego Madureira de Oliveira; Fábio Morato de Oliveira; Eduardo Magalhaes Rego; Fábio Pittella-Silva; Felipe Saldanha-Araujo
Journal:  Environ Mol Mutagen       Date:  2017-08-19       Impact factor: 3.216

Review 4.  The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpression.

Authors:  Leah C Young; Michael J Hendzel
Journal:  Biochem Cell Biol       Date:  2012-12-05       Impact factor: 3.626

Review 5.  Histone lysine demethylases as targets for anticancer therapy.

Authors:  Jonas W Højfeldt; Karl Agger; Kristian Helin
Journal:  Nat Rev Drug Discov       Date:  2013-11-15       Impact factor: 84.694

6.  Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.

Authors:  Masaharu Kogure; Masashi Takawa; Hyun-Soo Cho; Gouji Toyokawa; Kazuyuki Hayashi; Tatsuhiko Tsunoda; Takaaki Kobayashi; Yataro Daigo; Masanori Sugiyama; Yutaka Atomi; Yusuke Nakamura; Ryuji Hamamoto
Journal:  Cancer Lett       Date:  2013-04-18       Impact factor: 8.679

Review 7.  KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells.

Authors:  William L Berry; Ralf Janknecht
Journal:  Cancer Res       Date:  2013-05-03       Impact factor: 12.701

8.  The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL.

Authors:  E Matutes; K Owusu-Ankomah; R Morilla; J Garcia Marco; A Houlihan; T H Que; D Catovsky
Journal:  Leukemia       Date:  1994-10       Impact factor: 11.528

9.  Overexpression of KDM4 lysine demethylases disrupts the integrity of the DNA mismatch repair pathway.

Authors:  Samah W Awwad; Nabieh Ayoub
Journal:  Biol Open       Date:  2015-03-13       Impact factor: 2.422

10.  PARP1-dependent recruitment of KDM4D histone demethylase to DNA damage sites promotes double-strand break repair.

Authors:  Hanan Khoury-Haddad; Noga Guttmann-Raviv; Inbal Ipenberg; David Huggins; Anand D Jeyasekharan; Nabieh Ayoub
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

View more
  3 in total

Review 1.  KDM4B: A Nail for Every Hammer?

Authors:  Cailin Wilson; Adam J Krieg
Journal:  Genes (Basel)       Date:  2019-02-12       Impact factor: 4.096

Review 2.  The Diverse Roles of Histone Demethylase KDM4B in Normal and Cancer Development and Progression.

Authors:  Zhongze Wang; Huarui Cai; Erhu Zhao; Hongjuan Cui
Journal:  Front Cell Dev Biol       Date:  2022-02-02

3.  Heme, A Metabolic Sensor, Directly Regulates the Activity of the KDM4 Histone Demethylase Family and Their Interactions with Partner Proteins.

Authors:  Purna Chaitanya Konduri; Tianyuan Wang; Narges Salamat; Li Zhang
Journal:  Cells       Date:  2020-03-22       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.